“Nature’s randomised trials” have the potential to settle uncertainty surrounding the impact of lowering risk factors such as LDL-cholesterol on the risk of future cardiovascular events, and whether it actually matters how we lower them. Speaking at a recent meeting of cardiologists and endocrinologists in Melbourne, cardiologist and genetic epidemiologist Professor Brian Ference, currently the ...
Does it matter how we lower LDL-cholesterol? Answers from Mendelian randomisation studies
14 Mar 2019
Sponsored by Amgen Australia Pty Ltd